Biogen(US:BIIB)2025-10-30 12:30Financial Performance - Total revenue increased by 3% year-over-year to $2.53 billion in Q3 2025[59, 61, 64] - Launch products revenue grew 67% year-over-year, reaching $257 million in Q3 2025[19, 59] - GAAP diluted EPS increased by 19% year-over-year to $3.17, while Non-GAAP diluted EPS increased by 18% year-over-year to $4.81[59, 64] - The company generated $1.23 billion of free cash flow in Q3 2025[59] Product Performance - LEQEMBI achieved $121 million in in-market sales, demonstrating sustained sequential global demand growth[19, 48] - SKYCLARYS revenue grew 30% year-over-year and is now available in 34 markets globally[19, 52] - ZURZUVAE revenue increased by over 150% year-over-year, with 80% of prescriptions for first-line therapy[19, 55] Pipeline Advancement - Litifilimab Phase 3 studies for SLE are fully enrolled, with data expected in H2 2026[19, 34, 41] - A Phase 1 study was initiated for BIIB142, an IRAK4 degrader for autoimmune diseases[19, 21, 34, 35] - The company expects 3-4 potential new INDs[34, 35] Financial Guidance - Full year 2025 Non-GAAP diluted EPS is expected to be between $14.50 and $15.00[59] - Full year 2025 total revenue is expected to be approximately flat to increasing 1% at constant currency[59, 74] - The company expects to deliver $1 billion gross savings / $800 million net savings as part of the "Fit for Growth" initiative by the end of 2025[24, 79]